Idioma:

Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab

Berman, Horacio ; Rodríguez-Pintó, Ignasi ; Cervera, Ricard ; Morel, Nathalie ; Costedoat-Chalumeau, Nathalie ; Erkan, Doruk ; Shoenfeld, Yehuda ; Espinosa, Gerard

Autoimmunity reviews, 2013-09, Vol.12 (11), p.1085-1090 [Periódico revisado por pares]

Netherlands: Elsevier B.V

Texto completo disponível

Citações Citado por

Enviar para

Título:
Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab
Autor: Berman, Horacio ; Rodríguez-Pintó, Ignasi ; Cervera, Ricard ; Morel, Nathalie ; Costedoat-Chalumeau, Nathalie ; Erkan, Doruk ; Shoenfeld, Yehuda ; Espinosa, Gerard
Assuntos: Allergy and Immunology ; Anti-CD20 ; Antibodies, Monoclonal, Murine-Derived - therapeutic use ; Antiphospholipid Syndrome - blood ; Antiphospholipid Syndrome - drug therapy ; Antiphospholipid Syndrome - therapy ; Catastrophic antiphospholipid syndrome ; Catastrophic Illness - therapy ; Humans ; Immunoglobulins, Intravenous - therapeutic use ; Plasma Exchange ; Plasmapheresis ; Refractory ; Registries ; Rituximab ; Thrombosis - therapy
É parte de: Autoimmunity reviews, 2013-09, Vol.12 (11), p.1085-1090
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descrição: Abstract The catastrophic variant of the antiphospholipid syndrome (APS) is characterized by thrombosis in multiple organs developing over a short period of time. First-line treatment for the catastrophic APS is the combination of anticoagulation plus corticosteroids plus plasma exchange and/or intravenous immunoglobulin. Despite this regimen, the mortality remains high and new treatment options are needed. By a systematic review of the Catastrophic APS Registry (CAPS Registry), we identified 20 patients treated with rituximab. The purpose of this study is to describe the clinical manifestations, laboratory features, and outcomes of rituximab-treated CAPS patients. In addition, the rationale for using rituximab in catastrophic APS is discussed.
Editor: Netherlands: Elsevier B.V
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab

Berman, Horacio ; Rodríguez-Pintó, Ignasi ; Cervera, Ricard ; Morel, Nathalie ; Costedoat-Chalumeau, Nathalie ; Erkan, Doruk ; Shoenfeld, Yehuda ; Espinosa, Gerard

Netherlands: Elsevier B.V

Buscando em bases de dados remotas. Favor aguardar.